CA2246431A1 - Expression recombinee de proteines a partir de lignees cellulaires secretoires - Google Patents

Expression recombinee de proteines a partir de lignees cellulaires secretoires Download PDF

Info

Publication number
CA2246431A1
CA2246431A1 CA 2246431 CA2246431A CA2246431A1 CA 2246431 A1 CA2246431 A1 CA 2246431A1 CA 2246431 CA2246431 CA 2246431 CA 2246431 A CA2246431 A CA 2246431A CA 2246431 A1 CA2246431 A1 CA 2246431A1
Authority
CA
Canada
Prior art keywords
amylin
cell
cells
gene
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2246431
Other languages
English (en)
Inventor
Christopher B. Newgard
Philippe A. Halban
Karl D. Normington
Samuel A. Clark
Anice E. Thigpen
Fred Kruse
Dennis Mcgarry
Christian Quaade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagene Inc
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/589,028 external-priority patent/US6087129A/en
Application filed by Individual filed Critical Individual
Publication of CA2246431A1 publication Critical patent/CA2246431A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à des procédés de production de polypeptides hétérologues tels que l'amyline, à l'aide de lignées cellulaires obtenues par génie génétique. L'invention se rapporte également à des procédés de manipulation de cellules pour obtenir un haut niveau d'expression, à des procédés de production à grande échelle de protéines hétérologues, à des procédés de traitement de maladies in vivo à l'aide de systèmes d'administration viraux et de lignée cellulaires de recombinaison, et à des procédés destinés à isoler de nouveaux récepteurs de l'amyline.
CA 2246431 1996-01-19 1997-01-17 Expression recombinee de proteines a partir de lignees cellulaires secretoires Abandoned CA2246431A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/589,028 US6087129A (en) 1996-01-19 1996-01-19 Recombinant expression of proteins from secretory cell lines
US08/589,028 1996-01-19
US2842796P 1996-10-15 1996-10-15
US60/028,427 1996-10-15

Publications (1)

Publication Number Publication Date
CA2246431A1 true CA2246431A1 (fr) 1997-07-24

Family

ID=26703682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2246431 Abandoned CA2246431A1 (fr) 1996-01-19 1997-01-17 Expression recombinee de proteines a partir de lignees cellulaires secretoires

Country Status (4)

Country Link
EP (1) EP0910578A2 (fr)
AU (1) AU718254B2 (fr)
CA (1) CA2246431A1 (fr)
WO (1) WO1997026321A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CA2318376A1 (fr) * 1998-01-12 1999-07-15 Betagene, Inc. Compositions et procedes regulant la secretion de lignees de cellules neuroendocrines
WO1999035245A2 (fr) * 1998-01-12 1999-07-15 Board Of Regents, The University Of Texas System Procedes pour preparer et utiliser des cellules neuroendocriniennes humaines immortalisees
US6322962B1 (en) 1998-08-14 2001-11-27 Board Of Regents, The University Of Texas System Sterol-regulated Site-1 protease and assays of modulators thereof
EP1274720A4 (fr) 2000-04-12 2004-08-18 Human Genome Sciences Inc Proteines fusionnees a l'albumine
EP1463752A4 (fr) 2001-12-21 2005-07-13 Human Genome Sciences Inc Proteines de fusion d'albumine
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
CA2513213C (fr) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Proteines hybrides d'albumine
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
US20060094652A1 (en) * 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
JP2009514548A (ja) * 2005-11-03 2009-04-09 リアット・ミンツ ホルモン不均衡を診断、モニターおよび治療するため組成物、試薬およびキットおよびその方法
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
RU2008147398A (ru) * 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
WO2010080494A1 (fr) * 2008-12-19 2010-07-15 Tercica, Inc. Procédés d'identification de produits de dégradation dans un échantillon polypeptidique.
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
US10267769B2 (en) 2010-03-04 2019-04-23 Ventana Medical Systems, Inc. Processing system for processing specimens using acoustic energy
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9341639B2 (en) 2013-07-26 2016-05-17 Industrial Technology Research Institute Apparatus for microfluid detection
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
JP6989262B2 (ja) 2014-10-27 2022-01-05 アセコー インコーポレイテッド 皮下外来患者管理
CA2993275C (fr) 2015-08-20 2022-06-21 Aseko, Inc. Conseiller de therapie pour la gestion du diabete

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
DE69227517D1 (de) * 1991-08-08 1998-12-10 Amylin Pharmaceuticals Inc Produktion von peptid-amiden
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus

Also Published As

Publication number Publication date
EP0910578A2 (fr) 1999-04-28
AU718254B2 (en) 2000-04-13
WO1997026321A2 (fr) 1997-07-24
AU1750597A (en) 1997-08-11
WO1997026321A3 (fr) 1998-01-08

Similar Documents

Publication Publication Date Title
US6110707A (en) Recombinant expression of proteins from secretory cell lines
AU718254B2 (en) Recombinant expression of proteins from secretory cell lines
AU714852B2 (en) Methods and compositions for inhibiting hexokinase
CA2246268A1 (fr) Expression par recombinaison de proteines issues de lignees cellulaires secretoires
US5427940A (en) Engineered cells producing insulin in response to glucose
US5891717A (en) Methods and compositions for inhibiting hexokinase
HU219674B (hu) Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra
US5993799A (en) Methods of using genetically engineered cells that produce insulin in response to glucose
US20040132679A1 (en) Induction of pancreatic islet formation
EP1928504B1 (fr) Therapie de gene dans le foie
KR20080036015A (ko) 글루코오스 유도성 인슐린 발현 및 당뇨병 치료 방법
DE69527544T2 (de) Kombinationsvektoren zum austragen von genmaterial
JP2020535834A (ja) 遺伝子修飾されたベータ細胞による糖尿病の治療
AU687836B2 (en) Vectors for genetically engineered cells that produce insulin in response to glucose
CN120129753A (zh) 使用可溶性免疫检查点蛋白诱发免疫耐受的方法
US5792656A (en) Methods of preparing genetically engineered cells that produce insulin in response to glucose
AU783594B2 (en) Method of prophylaxis and treatment of diabetes
CA2186528A1 (fr) Cellules genetiquement modifiees en vue d'une transplantation
AU2006281912B2 (en) Liver-directed gene therapy
AU4720500A (en) Recombinant expression of proteins from secretory cell lines
CA2248638A1 (fr) Compositions et procedes d'inhibition de l'hexokinase
DAVIES ENGINEERING A SURROGATE (-CELL
TW201923070A (zh) 以基因改造β細胞治療糖尿病
AU1835801A (en) Recombinant expression of proteins from secretory cell lines

Legal Events

Date Code Title Description
FZDE Dead